Bradykinin causes angioedema by forcing open tiny gaps between the cells lining your blood vessels, allowing fluid to leak into deeper tissues and produce rapid, sometimes dramatic swelling. Unlike allergic angioedema driven by histamine, bradykinin-mediated angioedema doesn’t respond to antihistamines, epinephrine, or steroids, which makes understanding the underlying mechanism more than academic. It directly shapes how the condition is recognized and treated.
The Contact System: Where Bradykinin Comes From
Bradykinin doesn’t float around in your blood waiting to cause trouble. It’s generated on demand through a cascade called the contact system, sometimes referred to as the kallikrein-kinin system. The sequence works like a chain of dominoes. First, a protein called Factor XII gets activated, often when blood contacts damaged or foreign surfaces. Activated Factor XII then converts another circulating protein, prekallikrein, into its active form, plasma kallikrein. Plasma kallikrein then clips a larger molecule called high-molecular-weight kininogen, releasing bradykinin as a small fragment.
There’s a built-in amplification loop: plasma kallikrein can activate more Factor XII, which produces more kallikrein, which releases more bradykinin. In healthy people, a regulatory protein called C1 inhibitor keeps this loop in check by inactivating both Factor XII and plasma kallikrein. When C1 inhibitor is missing or dysfunctional, the cascade runs unchecked, and bradykinin levels spike.
What Bradykinin Does to Blood Vessels
Once released, bradykinin locks onto a specific receptor (the B2 receptor) on the endothelial cells that line blood vessel walls. This triggers a signaling chain inside those cells that disassembles the molecular “zippers” holding them tightly together. These zippers are known as adherens junctions and tight junctions. When they come apart, gaps open between cells, and plasma fluid rushes out into surrounding tissue.
Bradykinin also causes blood vessels to dilate, which increases local blood flow and blood pressure at the capillary level, pushing even more fluid through those newly opened gaps. The combined effect, more fluid arriving and more gaps for it to escape through, produces the deep, firm swelling characteristic of angioedema. Research on human endothelial cells shows that blocking the B2 receptor strongly reduces both the junction disassembly and the increased permeability, confirming this receptor as the central switch.
Where Swelling Typically Occurs
Bradykinin-mediated angioedema favors the head, neck, lips, mouth, tongue, larynx, pharynx, and the tissue below the vocal cords. Swelling in the abdomen is also common, particularly in hereditary forms, and can cause intense cramping that mimics a surgical emergency. Unlike histamine-driven swelling, bradykinin angioedema does not produce hives or itching. The skin over the swollen area typically looks normal in color, and the edema is firm and non-pitting.
Swelling of the face and tongue progresses to involve the larynx in roughly 30% of cases. Untreated laryngeal involvement carries a mortality rate of about 25%, which is why rapid identification of the underlying mechanism matters so much in an emergency.
Why Some People Are Vulnerable
Hereditary Angioedema
The most well-known cause of bradykinin-mediated angioedema is hereditary angioedema (HAE), a genetic condition in which C1 inhibitor is either produced in insufficient amounts or doesn’t function properly. Without enough working C1 inhibitor, the contact system amplification loop spins freely, generating bursts of excess bradykinin that trigger unpredictable attacks. Most people with HAE experience their first episode in childhood or adolescence, and attacks can be provoked by stress, minor trauma, dental procedures, or hormonal changes.
A smaller subset of patients have normal C1 inhibitor levels but carry mutations in other genes involved in the pathway, including the gene for Factor XII, plasminogen, or kininogen itself. These mutations either increase bradykinin production or slow its breakdown, tipping the balance toward excess.
ACE Inhibitor Angioedema
ACE inhibitors, one of the most widely prescribed classes of blood pressure medication, work by blocking an enzyme that converts a hormone involved in raising blood pressure. That same enzyme is also responsible for breaking down bradykinin. When the enzyme is inhibited, bradykinin accumulates instead of being cleared, and in susceptible individuals, the excess triggers angioedema. Among patients prescribed ACE inhibitors, about 0.7% develop angioedema within five years. Roughly half of those cases appear within the first week of treatment, but the rest can emerge weeks, months, or even years later, which often delays the connection between the drug and the swelling.
How It Differs From Allergic Angioedema
The distinction between bradykinin and histamine-driven angioedema has direct practical consequences. Histamine-mediated angioedema typically comes with hives, itching, and sometimes full anaphylaxis including wheezing and a drop in blood pressure. Standard emergency treatments, epinephrine, antihistamines, and corticosteroids, work well. Bradykinin-mediated angioedema produces none of these allergic features. The swelling appears without hives or itching and shows no response, or only minimal response, to epinephrine, antihistamines, or steroids.
This distinction is critical because patients experiencing a bradykinin-mediated attack in the throat or tongue may not improve with standard allergy protocols, and airway compromise can escalate quickly. The absence of hives is one of the most reliable clinical clues pointing toward a bradykinin mechanism.
Treatments That Target Bradykinin Directly
Because the problem isn’t histamine, effective treatment requires interrupting the bradykinin pathway at specific points. Several approaches now exist, each aimed at a different link in the chain.
- B2 receptor blockers. Icatibant is a synthetic molecule that competes directly with bradykinin for the B2 receptor on blood vessel cells, with binding affinity similar to bradykinin itself. By occupying the receptor, it prevents bradykinin from triggering the permeability cascade. It’s injected under the skin during an acute attack.
- C1 inhibitor replacement. For people with hereditary angioedema caused by C1 inhibitor deficiency, replacing the missing protein restores the natural brake on the contact system. This can be used to treat acute attacks or given regularly to prevent them.
- Plasma kallikrein inhibitors. These block the enzyme that clips bradykinin free from kininogen, reducing how much bradykinin is generated in the first place. One preventive option, a monoclonal antibody targeting plasma kallikrein, brought the proportion of attack-free patients from 0% before treatment to roughly 66% over a year in real-world use, with 80% of patients attack-free during the first six months.
For ACE inhibitor angioedema, the most important step is stopping the medication and switching to an alternative blood pressure drug. Swelling episodes typically resolve once the drug is cleared, though some patients experience a final flare during the transition period.
Why the Mechanism Matters for You
If you or someone you know experiences recurrent swelling episodes without hives, especially involving the face, lips, tongue, or abdomen, the bradykinin pathway is a likely explanation. Recognizing that this type of swelling operates through a completely different biological mechanism than allergic reactions explains why standard allergy treatments fail and why targeted therapies exist. It also explains why timing can be confusing: ACE inhibitor angioedema can appear years into treatment, and hereditary forms can strike unpredictably throughout life. Identifying the mechanism is what opens the door to treatments that actually work.